Pay in 4 interest-free payments of $6.47 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Study: TripleHormone Receptor Agonist Retatrutide for Obesity (Phase 2 Trial, NEJM) Drug: Retatrutide a triple agonist (GLP-1, GIP, and glucagon receptors) Key Findings: Up to 28.7% mean weight loss at higher doses Marked improvements in insulin sensitivity and cardiometabolic risk factors Weight loss approaching outcomes seen with bariatric surgery, without surgery What makes Retatrutide unique is its triple-hormone mechanism, simultaneously targeting appetite regulation, energy expenditure, and glucose metabolism
Your provider will determine the best route for you
F.Iturbe-OrmaetxeI.RubioM
Clinical trial data strongly supports Retatrutide use in women
US$ 29.13
US$ 29.47
US$ 20.73
US$ 29.16
